|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tissue factor pathway inhibitor and antithrombin trial results显示文摘 | LaRosa SP Opal SM | 2005 | Crit-Care-Clin2005，21，3： | 1 |
| 2 | The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology,and results显示文摘 | Dhainaut JF Laterre PF LaRosa SP | 2003 | Crit Care Med2003，31，9： | 1 |
| 3 | Phase 2 trial of eritoran tetrasodium (E5564), a toll- like receptor 4 antagonist, in patients with severe sepsis显示文摘 | Tidswell M Tillis W Larosa SP | 2010 | Crit Care Med2010，38，1： | 1 |
| 4 | Sepsis:menu of new approaches replaces one therapy for all显示文摘 | Larosa SP | 2002 | Cleve Clin J Med2002，69，1： | 1 |
| 5 | Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in pa- tients with severe sepsis 显示文摘 | Tidswell M Tillis W Larosa SP et ol | 2010 | Crit Care Med2010，38，1： | 1 |
| 6 | Immune aspects of sepsis and hope for new therapeutics显示文摘 | Larosa SP Opal SM | 2012 | Current infectious disease reports2012，14，5： | 1 |
| 7 | Biomarkers: the future 显示文摘 | LaRosa SP Opal SM | 2011 | Crit Care Clin2011，27，2： | 1 |
| 8 | Phase 2 trial of eritoran tetrasodium(E5564),a toll-like receptor 4 antagonist,in patients with severe sepsis显示文摘 | Tidswell M Tillis W Larosa SP | | 0，，： | 1 |
| 9 | Tissue factor pathway inhibitor andanti thrombin trial results 显示文摘 | LaRosa SP Opal SM | 2005 | Crit Care Clin2005，21，3： | 1 |
| 10 | Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of Drotrecogin Alfa (activated)显示文摘 | Opal SM Garber GE LaRosa SP | 2003 | Clin Infect Dis2003，37，1： | 1 |
| 11 | Biomarkers : the future 显示文摘 | LaRosa SP Opal SM | 2011 | Crit Care Clin2011，27，2： | 1 |
| 12 | Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in pa- tients with severe sepsis显示文摘 | Tidswell M Tillis W Larosa SP | 2010 | Cfit Care Med2010，38，1： | 1 |
| 13 | Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued显示文摘 | Gordon SM LaRosa SP Kalmadi S | | 0，，02： | 1 |
| 14 | Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonis, in patients with severe sepsis 显示文摘 | TIDSWELL M TILLS W LAROSA SP et ol | 2010 | Crit Care Med2010，38，1： | 1 |
| 15 | Tissue factor pathway inhibitor and anitithrombintrial results显示文摘 | Larosa SP Opal SM | 2005 | Crit Care Clin2005，21，3： | 1 |
| 16 | Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor a7 subunit gene knockout mice显示文摘 | van Maanen MA Stoof SP Larosa G J | 2010 | Ann Rheum Dis2010，69，9： | 1 |
| 17 | Should prophylaxis for pneumocystis carinii pneumonia in solid organ tranplant recipivnt ever be discontinued显示文摘 | Gordon SM LaRosa SP Kalmadi S | 1999 | CID1999，28，2： | 1 |
| 18 | Role of the chol- inergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice显示文摘 | Van Maanen MA Stoof SP Larosa GJ | 2010 | Ann Rheum Dis2010，69，9： | 1 |
| 19 | Phase 2 trial of tetrasodium ( E5564 ), a toll-like receptor 4 antagonist, in patients with severe sepsis显示文摘 | Tidswell M Tillis W Larosa SP | 2010 | Crit Care Med2010，38，9： | 1 |
| 20 | Phase 2 trial of tetrasodium (E5564),a toll-like receptor 4 antagonist,in patients with severe sepsis显示文摘 | TIDSWELL M TILLIS W LAROSA SP | 2010 | Crit Care Med2010，38，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员